BioAtla (NASDAQ:BCAB) Stock Quotes, Forecast and News Summary

Q: What sector and industry does BioAtla (BCAB) operate in?

BioAtla is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

BioAtla Stock (NASDAQ: BCAB) stock price, news, charts, stock research, profile.

Open	$1.45
Close	$1.39
Volume / Avg.	1.97M / 1.15M
Day Range	$1.33 - $1.50
52 Wk Range	1.14 - 4.02
Market Cap	$67.20M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	33
Short Interest	11.26%
Days to Cover	6.96

Recent News

'Big Short' Investor Michael Burry's China Bet Pays Off As Top Picks Surge Nearly 60% In 2 Months

Michael Burry, the investor renowned for his prescient bet against the housing market before the 2008 financial crisis, has seen his recent wager on Chinese stocks pay significant dividends.

Kaustubh Bagalkote

'Big Short' Fame Michael Burry Bets Big On China, Reveals Alibaba As Top Holding — JD.com And Baidu Also Feature On Scion's Portfolio

Famed investor Michael Burry, known for his prescient bet against the housing market before the 2008 financial crisis, has made significant changes to his hedge fund's portfolio in the second quarter of 2024.

Kaustubh Bagalkote

Around $2M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

The Dow Jones index closed higher by around 250 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

May

Sep

Nov

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$1.45
Close	$1.39
Volume / Avg.	1.97M / 1.15M
Day Range	$1.33 - $1.50
52 Wk Range	1.14 - 4.02
Market Cap	$67.20M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	33
Short Interest	11.26%
Days to Cover	6.96

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy BioAtla (BCAB) stock?

You can purchase shares of BioAtla (NASDAQ:BCAB) through any online brokerage.

View our list of the best stock brokerages

Who are BioAtla (BCAB) competitors?

Other companies in BioAtla’s space includes: CytomX Therapeutics (NASDAQ:CTMX), Cellectar Biosciences (NASDAQ:CLRB), Immuneering (NASDAQ:IMRX), Aligos Therapeutics (NASDAQ:ALGS) and Armata Pharmaceuticals (AMEX:ARMP).

What is the forecast, or price target, for BioAtla (BCAB) stock?

BioAtla has a consensus price target of $14.17.

What is the current price for BioAtla (BCAB)?

The stock price for BioAtla (NASDAQ: BCAB) is $1.39 last updated November 21, 2024 at 5:08 PM EST.

Does BioAtla (BCAB) pay a dividend?

There are no upcoming dividends for BioAtla.

When is BioAtla (NASDAQ:BCAB) reporting earnings?

BioAtla’s Q3 earnings are confirmed for Thursday, November 7, 2024.

Is BioAtla (BCAB) going to split?

There is no upcoming split for BioAtla.

What sector and industry does BioAtla (BCAB) operate in?

BioAtla is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

BioAtla

BioAtla (BCAB) Forecast